Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › evoke / evoke+

evoke / evoke+

Semaglutide · Early Alzheimer's disease

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
Early Alzheimer's disease
Official title
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2021-05 → 2025-09
Participants
3680
Duration
104 weeks
Registry
NCT04777396, NCT04777409

Outcomes in the indication

evoke / evoke+ Semaglutide · Early Alzheimer's disease · 104 weeks · n = 3680 seed

Primary endpoint (CDR-SB) not met (announced Nov 2025)

MeasureDrugControlDifference (95 % CI)Status
CDR-SB, change from baseline evoke
week 104
+2.3+2.3−0.1 (−0.3 to +0.2) points (0-18)verified
CDR-SB, change from baseline evoke+
week 104
+2.2+2.1+0.1 (−0.2 to +0.4) points (0-18)verified
Verbatim quotes (2)
  • CDR-SB, change from baseline
    mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)
  • CDR-SB, change from baseline
    mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)

Related registry entries

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
evoke / evoke+
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Alzheimer'sPhase 3completed2021-05 → 2025-091840CDR-SB primary endpoint not metNCT04777396
EVOKE Plus
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Alzheimer'sPhase 3completed2021-05 → 2025-091840CDR-SB primary endpoint not met (with evoke)NCT04777409

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: evoke / evoke+. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/evoke-evoke/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.